Topamax Birth Defect Lawsuits 2026: The $4M, $11M & $3M Verdicts, the Settlement — and Who Can Still File
In 2026, the Topamax birth-defect litigation is effectively closed: after three bellwether jury verdicts against Janssen Pharmaceuticals and a 2014 global settlement of 76 complaints, the cases have wound down, and drug-safety trackers report that no law firms are currently accepting new Topamax cases. The story still matters, because it set the modern standard for how birth-defect claims against a drug maker are proved.
Key facts
- 1997: the FDA approves Topamax (topiramate) for epilepsy; it is later approved for migraine prevention and becomes available as a generic in 2006.
- March 2011: the FDA issues a safety warning that first-trimester Topamax use raises the risk of oral clefts — cleft lip and cleft palate — and moves the drug from pregnancy category C to category D.
- 2013–2014: three Philadelphia bellwether juries award $4 million, $11 million and $3 million to families of children born with birth defects.
- 2014: Janssen agrees to a global settlement covering 76 complaints; the individual amounts stay confidential.
- May 2016: Pennsylvania’s Superior Court upholds the $3 million verdict, affirming that Janssen failed to warn doctors of the birth-injury risk.
What Topamax is — and why it reached so many women of childbearing age
Topamax is the brand name of topiramate, an anticonvulsant — a drug that calms abnormal electrical activity in the brain. Doctors prescribe it to treat epilepsy and to prevent migraine headaches, and for years it was also promoted for uses the FDA had never approved. Because migraines disproportionately affect women in their childbearing years, large numbers of women took the drug during the exact window when a developing embryo is most vulnerable. According to litigation accounts, some of those women were taking it for migraines when they became pregnant, and their babies were later born with cleft lips, cleft palates and other congenital malformations.
The 2011 FDA warning that changed everything
In March 2011, the FDA announced that babies born to mothers who took Topamax during the first trimester face a higher risk of oral clefts — openings in the lip or the roof of the mouth that form when facial structures fail to fuse during early pregnancy, and that are typically repaired through multiple surgeries in childhood. The FDA moved Topamax from pregnancy category C (risk cannot be ruled out) to pregnancy category D (positive evidence of fetal risk from human data), and urged doctors to avoid prescribing it to pregnant women and women of childbearing age at high risk of pregnancy. The warning cited data from the Antiepileptic Drug Pregnancy Registry, which reported a 3.8 percent prevalence of oral birth defects among children exposed to the drug during the first trimester — the window when oral clefts develop, sometimes before a woman even knows she is pregnant.
The three bellwether trials that forced a settlement
Families sued Janssen — the Johnson & Johnson subsidiary that makes Topamax — arguing the company knew of the birth-defect signal and failed to warn doctors. The litigation’s turning point came in three Philadelphia bellwether trials, test cases chosen to show both sides how juries would respond: in October 2013 a jury awarded $4 million to the family of Blake Czimmer, born with numerous birth defects; in November 2013 a jury awarded $11 million to the family of Brayden Powell, born with a cleft lip and other deformities that could require five surgeries; and in March 2014 a jury awarded $3 million to the family of a five-year-old boy. In each case the jury found that Janssen had negligently failed to warn of the birth-defect risk. A fourth case settled confidentially during trial. Those verdicts set the price of taking the remaining cases to court, and they paved the way for a global resolution.
The 2014 global settlement — and what families received
In 2014, Janssen and Johnson & Johnson agreed to settle 76 Topamax birth-defect complaints in Pennsylvania state court, according to contemporaneous reports, while the companies faced at least 60 more cases centralized in Philadelphia. The settlement amounts were never disclosed publicly, and the companies admitted no liability. What is documented is the pattern: once the bellwether verdicts showed juries would punish the failure to warn, mass settlement followed. That pattern — verdicts first, settlement second — is how nearly every major drug mass tort in the United States has resolved.
Can you still file a Topamax lawsuit in 2026?
Honestly: probably not through the old litigation. Every state sets a statute of limitations — a legal deadline after which a claim can no longer be filed — and most Topamax claims arose from births between roughly 2006 and 2011, long before the 2011 warning. Many states allow extra time when the injured person was a minor or when the harm was only recently discovered, which is why some cases survived into the 2010s. But with the consolidated litigation resolved more than a decade ago and drug-safety trackers reporting, as of October 2026, that they know of no attorneys actively accepting new Topamax cases, the practical door has nearly closed. Anyone who believes a child was harmed should still speak to a lawyer promptly, because exceptions exist and deadlines vary by state — but expectations should be realistic.
What the Topamax litigation teaches about drug birth-defect claims
The Topamax cases clarified a powerful legal principle: a brand-name drug maker has a duty to warn — a legal obligation to tell doctors about risks it knew or should have known — and it cannot hide behind the FDA’s approval of its label. When Janssen argued it could not strengthen its warning without FDA permission, the Pennsylvania appeals court disagreed in May 2016, holding that the company still owed doctors a warning. For families, the lesson is about timing: oral clefts develop in the first trimester, often before pregnancy is confirmed, which is why the warning urged doctors to counsel women of childbearing age before they conceive — not after a positive test. If a medication’s warning reaches your doctor too late, the injury may already be done.
If you took a medication during pregnancy: the records that matter
Every drug-injury lawyer will ask the same questions, so gathering the answers early strengthens any claim: the exact dates you took the medication and the dose; the pharmacy records and prescribing doctor’s notes; whether the doctor discussed birth-defect risks before prescribing; the child’s diagnosis and surgical records; and when you first connected the drug to the injury. Keep every label, receipt and medical record, and do not stop or restart any medication without your doctor’s guidance. For explained breakdowns of major drug litigations and how courts handle them, you can also follow the Problem Solved channel on YouTube.
Related reading: drug litigation over pregnancy injuries follows similar legal paths — see our guides to the Zofran birth-defect lawsuit, the cerebral palsy birth-injury claims, and the Tylenol lawsuits reinstated in 2026.
Who Benefits From This — and Who Does Not
This article is for readers trying to place a Topamax pregnancy injury in a litigation that is effectively closed — and to judge honestly whether any door is still open.
Who benefits:
- Families of children born with oral clefts after first-trimester Topamax exposure: the injuries proven in the three bellwether trials ($4 million in October 2013, $11 million in November 2013, $3 million in March 2014). How to use this article: compare your records — prescription dates and dose, pharmacy records, whether the doctor discussed birth-defect risks, and the child's diagnosis and surgical records — against the checklist in "the records that matter."
- Women who took Topamax during pregnancy and want the warning timeline: the FDA's March 2011 warning moved the drug from pregnancy category C to category D and cited a 3.8 percent prevalence of oral birth defects in first-trimester exposure. How to use this article: judge whether your doctor was counselled — and counselled you — before conception, not after a positive test.
- Readers studying how drug birth-defect claims are proved: the duty-to-warn principle, confirmed when Pennsylvania's Superior Court upheld the $3 million verdict in May 2016. How to use this article: follow the pattern — bellwether verdicts first, global settlement of 76 complaints second — that resolved this litigation.
Who does not benefit:
- Anyone expecting to join a live Topamax filing program: the consolidated litigation resolved more than a decade ago, and drug-safety trackers report that no attorneys are actively accepting new Topamax cases as of October 2026.
- Anyone whose claim rests on a recent prescription alone: most claims arose from births between roughly 2006 and 2011, before the 2011 warning, so state statutes of limitations have run on nearly all of them.
- Anyone looking for medical advice about topiramate: this article is general information, not medical advice — do not stop or restart any medication without your doctor's guidance.
Read also: Zofran birth-defect lawsuit.
Frequently asked questions
Is Topamax still prescribed today?
Yes. Topamax and generic topiramate remain on the market for epilepsy and migraine prevention, but the FDA label now carries the strengthened pregnancy warning and the category D classification, so doctors are expected to counsel women of childbearing age before prescribing it.
Which birth defects were linked to Topamax?
The core allegation was oral clefts — cleft lip and cleft palate — from first-trimester exposure, the injuries proven in the bellwether trials. Lawsuits also alleged other congenital malformations, and the FDA warned broadly about fetal risk.
How much did the verdicts and settlement pay?
The three bellwether verdicts were $4 million (October 2013), $11 million (November 2013) and $3 million (March 2014, upheld on appeal in May 2016). The 2014 global settlement of 76 complaints was confidential, so individual amounts are not public.
Why are no new Topamax cases being filed?
The consolidated litigation resolved more than a decade ago, and most claims arose from births before the 2011 warning, so state statutes of limitations have run on nearly all of them. As of October 2026, drug-safety trackers report no attorneys actively accepting new Topamax cases.
Who benefits most from this Topamax article?
Families of children born with oral clefts after first-trimester Topamax exposure — the injuries proven in the $4 million, $11 million and $3 million bellwether verdicts — and women who took Topamax during pregnancy and want to understand the 2011 FDA warning and the duty-to-warn principle behind the litigation.
How do I start checking a Topamax claim?
Gather the exact dates and dose you took the medication, pharmacy records, the prescribing doctor's notes, whether the doctor discussed birth-defect risks before prescribing, the child's diagnosis and surgical records, and when you first connected the drug to the injury — then speak to a lawyer promptly, keeping expectations realistic, since the consolidated litigation resolved more than a decade ago and trackers report no attorneys actively accepting new cases.
General information only, not legal advice. If you believe a medication harmed your child, consult a qualified attorney in your state promptly, because filing deadlines vary.